15 Feb 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Gerresheimer, one-of-the-leading worldwide partners of the pharma and healthcare industry, has closed the 2012 financial year with significant growth in revenues and profits. Gerresheimer recorded substantial growth in revenues of 11.4 percent. In particular Gerresheimer achieved strong growth in the pharma segment coupled with good revenue results in the cosmetic glass business and the life science research segment.
Gerresheimer increased its operating result (adjusted EBITDA) by 8.8 percent to $315.87 million (EUR 236.5 million) in the 2012 financial year. The adjusted EBITDA margin amounts to 19.4 percent, compared to the prior year's 19.9 pecent. Net income rose by 22.2 percent to $88.82 million (EUR 66.5 million). Earnings per share rose by 19.3 percent and adjusted earnings per share increased by 4.9 percent to $3.42 (EUR 2.56).
The company is also focusing on growth in the emerging markets. In April 2012 Gerresheimer acquired Neutral Glass, one-of-India's leading manufacturers of pharmaceutical vials. This was followed in December 2012 by the acquisition of the Indian company Triveni, the regional market leader for plastic pharmaceutical packaging and closures. Gerresheimer intends to achieve both organic growth and growth through acquisitions in the future.
Mr Uwe Röhrhoff, CEO, Gerresheimer, said that, "We achieved all our targets in 2012. We recorded another year of strong growth in our business activities with the pharmaceutical sector, which once again proved to be relatively immune to cyclical effects. We are investing heavily in expanding our production capacity for medical devices such as prefilled glass syringes, insulin pens and inhalers. We are also focusing on the fast-growing emerging markets, especially in China, Brazil and India. In 2012 we succeeded in expanding our position in India in particular with the acquisition of two companies there."